西黄胶囊联合康艾注射液治疗乳腺癌疗效分析
|
摘要
目的评价西黄胶囊联合康艾注射液对乳腺癌化疗患者肿瘤标志物、细胞免疫功能及毒副反应的影响,为改善乳腺癌患者的生活质量提供理论依据。方法随机将郑州大学第五附属医院收治的80例乳腺癌患者分为观察组和对照组,每组各40例,对照组采用EC序贯T化疗方案并给予康艾注射液,观察组在对照组的基础上联合西黄胶囊。每个疗程化疗前以及21天后分别检测两组乳腺癌患者肿瘤标志物、T淋巴细胞亚群、NK细胞水平,以及比较两组化疗前后毒副反应和生活质量的变化。结果化疗前两组乳腺癌患者乳腺癌肿瘤标志物水平、T淋巴细胞亚群水平以及NK细胞活性的比较无显著差异(P>0.05)。化疗后两组患者分别与化疗前相比,肿瘤标志物(CA153、CEA和CA125)水平降低,T淋巴细胞亚群(CD3~+、CD4~+、CD4~+/CD8~+)以及NK细胞活性升高,CD8~+降低,有显著差异(P<0.05),与化疗后对照组相比,观察组经治疗后肿瘤标志物(CA153、CEA和CA125)水平降低,T淋巴细胞亚群中CD3~+、CD4~+、CD4~+/CD8~+升高,然而CD8~+降低,组间比较差异显著(P<0.05)。观察组白细胞减少程度显著小于对照组,有统计学意义(χ~2=7.44,P=0.006),其他不良反应差异无显著差异(P>0.05);。观察组35.00%(14/40)患者KPS提高幅度高于对照组(15.00%, 6/40)(χ~2=5.64,P=0.018);观察组45.00%患者体重增加,高于对照组(20.00%)(χ~2=6.66,P=0.036)。结论西黄胶囊联合康艾注射液作为乳腺癌患者辅助治疗具有良好的效果,降低肿瘤标志物,提高患者机体免疫力,一定程度上减轻化疗的毒副反应,改善患者生活质量。
Objective To evaluate the effects of Xihuang capsule combined with Kangai injection on tumor markers, cellular immune function and toxic side effects in patients with breast cancer chemotherapy, and to provide a theoretical basis for improving the quality of life of breast cancer patients.Methods Totally 80 patients with breast cancer admitted to our hospital were enrolled in the study. The subjects were divided into observation group and control group by random number table, 40 patients in each group. The control group was treated with EC sequential T chemotherapy and Kangai injection. The observation group was combined with Xihuang capsule on the basis of the control group. Tumor markers, T lymphocyte subsets and NK cells in breast cancer patients were measured before and after each course of chemotherapy, and the changes in toxicity and quality of life before and after chemotherapy were compared between the two groups.Results There was no significant difference in breast cancer marker levels, T lymphocyte subsets and NK cell activity between observation group and control group of breast cancer patients before chemotherapy(P>0.05). After chemotherapy, the levels of tumor markers(CA153, CEA, and CA125) were decreased in the two groups, and the T lymphocyte subsets(CD3~+, CD4~+, CD4~+/CD8~+) and NK cells were increased, and CD8~+ was decreased. Significant differences(P<0.05), compared with the control group after chemotherapy, the levels of tumor markers(CA153, CEA and CA125) decreased in the observation group, and CD3~+, CD4~+, CD4~+/CD8~+ in the T lymphocyte subsets increased. However, CD8~+ decreased, and the difference between groups was significant(P<0.05).The leukocytopenia in the observation group was significantly smaller than that in the control group(χ~2 = 7.44, P=0.006), and there was no significant difference in other toxicities(P>0.05). In the observation group, 35.00%(14/40) patients had a higher increase in KPS than the control group(15.00%, 6/40)(χ~2 = 5.64, P=0.018); in the observation group, 45.00% of the patients gained weight, which was higher than the control group(20.00%)(χ~2 = 6.66, P=0.036).Conclusion Kangai injection combined with Xihuang Capsule has good effect as adjuvant therapy for breast cancer patients, reduces tumor markers, improves the body immunity of patients, and reduces the toxicity and side effects of chemotherapy to some extent and improves the quality of life of patients.
Objective To evaluate the effects of Xihuang capsule combined with Kangai injection on tumor markers, cellular immune function and toxic side effects in patients with breast cancer chemotherapy, and to provide a theoretical basis for improving the quality of life of breast cancer patients.Methods Totally 80 patients with breast cancer admitted to our hospital were enrolled in the study. The subjects were divided into observation group and control group by random number table, 40 patients in each group. The control group was treated with EC sequential T chemotherapy and Kangai injection. The observation group was combined with Xihuang capsule on the basis of the control group. Tumor markers, T lymphocyte subsets and NK cells in breast cancer patients were measured before and after each course of chemotherapy, and the changes in toxicity and quality of life before and after chemotherapy were compared between the two groups.Results There was no significant difference in breast cancer marker levels, T lymphocyte subsets and NK cell activity between observation group and control group of breast cancer patients before chemotherapy(P>0.05). After chemotherapy, the levels of tumor markers(CA153, CEA, and CA125) were decreased in the two groups, and the T lymphocyte subsets(CD3~+, CD4~+, CD4~+/CD8~+) and NK cells were increased, and CD8~+ was decreased. Significant differences(P<0.05), compared with the control group after chemotherapy, the levels of tumor markers(CA153, CEA and CA125) decreased in the observation group, and CD3~+, CD4~+, CD4~+/CD8~+ in the T lymphocyte subsets increased. However, CD8~+ decreased, and the difference between groups was significant(P<0.05).The leukocytopenia in the observation group was significantly smaller than that in the control group(χ~2 = 7.44, P=0.006), and there was no significant difference in other toxicities(P>0.05). In the observation group, 35.00%(14/40) patients had a higher increase in KPS than the control group(15.00%, 6/40)(χ~2 = 5.64, P=0.018); in the observation group, 45.00% of the patients gained weight, which was higher than the control group(20.00%)(χ~2 = 6.66, P=0.036).Conclusion Kangai injection combined with Xihuang Capsule has good effect as adjuvant therapy for breast cancer patients, reduces tumor markers, improves the body immunity of patients, and reduces the toxicity and side effects of chemotherapy to some extent and improves the quality of life of patients.
引文
[1] 陈万青,郑荣寿.中国女性乳腺癌发病死亡和生存状况[J].中国肿瘤临床.2015,42(13):668-674.
[2] Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells[J]. Nature. 2015,526(7571): 131-5.
[3] 江泽飞.乳腺癌治疗决策:从个体化治疗到精准医学[J].中国实用外科杂志.2015,35(7):697-700.
[4] 马静,魏素菊.三阴乳腺癌的最新治疗进展[J].中国肿瘤临床.2011,38(19):1234-1238.
[5] 周阿高,李琰.中医药对乳腺癌患者生存质量影响的Meta分析[J].中国实验方剂学杂志.2012,18(5):220-222.
[6] 周斌,刘世伟,高国璇,等.2016年NCCN乳腺癌临床实践指南(第1版)更新与解读[J].中国实用外科杂志.2016,36(10):1066-1072.
[7] Bangaru SD, Kozarsky PE, Lee DJ, et al. A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease[J]. World J Oncol. 2015,6(4): 416-420.
[8] Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk[J]. N Engl J Med. 2015,372(23): 2243-57.
[9] 宋涛,曾祥刚,李星宇.术前化疗对乳腺癌患者术中顺苯磺阿曲库铵肌松效应的影响[J].贵州医药.2014,38(9):822-824.
[10] 郑颖娟,汪森明.化疗药物对T淋巴细胞及其亚群影响的体外探讨[J].中国肿瘤临床.2005,32(6):311-313.
[11] 葛依工.移植性肝癌大鼠外周血和脾脏T细胞亚群变化的动态观察[J].第二军医大学学报.1989,10(3):247.
[12] 熊立凡,王鸿利.实验诊断学“规范检查”与循证医学[J].中国实验诊断学.2006,10(1):7-12.
[13] 赵斌华,荆永志.辅助性T细胞和抑制性T细胞对免疫反应的调控作用[J].国外医学(免疫学分册).1982,5(1):1-7.
[14] Zar ZM, Singer DR. Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis[J]. Pharmacogenomics. 2016, 17(10): 1189-1205.
[15] 金娟,李志鸿.西黄丸联合化疗治疗乳腺癌30例[J].中华中医药杂志.2010,25(5):715-716.
[16] 任贵兵,王磊,张府恒,等.黄连素对乳腺癌大鼠的治疗作用[J].中华实用诊断与治疗杂志,2017,31(8):747-750.
[2] Lawson DA, Bhakta NR, Kessenbrock K, et al. Single-cell analysis reveals a stem-cell program in human metastatic breast cancer cells[J]. Nature. 2015,526(7571): 131-5.
[3] 江泽飞.乳腺癌治疗决策:从个体化治疗到精准医学[J].中国实用外科杂志.2015,35(7):697-700.
[4] 马静,魏素菊.三阴乳腺癌的最新治疗进展[J].中国肿瘤临床.2011,38(19):1234-1238.
[5] 周阿高,李琰.中医药对乳腺癌患者生存质量影响的Meta分析[J].中国实验方剂学杂志.2012,18(5):220-222.
[6] 周斌,刘世伟,高国璇,等.2016年NCCN乳腺癌临床实践指南(第1版)更新与解读[J].中国实用外科杂志.2016,36(10):1066-1072.
[7] Bangaru SD, Kozarsky PE, Lee DJ, et al. A Bystander Effect of Lung Cancer Chemotherapy on Chronic Echinococcal Disease[J]. World J Oncol. 2015,6(4): 416-420.
[8] Easton DF, Pharoah PD, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk[J]. N Engl J Med. 2015,372(23): 2243-57.
[9] 宋涛,曾祥刚,李星宇.术前化疗对乳腺癌患者术中顺苯磺阿曲库铵肌松效应的影响[J].贵州医药.2014,38(9):822-824.
[10] 郑颖娟,汪森明.化疗药物对T淋巴细胞及其亚群影响的体外探讨[J].中国肿瘤临床.2005,32(6):311-313.
[11] 葛依工.移植性肝癌大鼠外周血和脾脏T细胞亚群变化的动态观察[J].第二军医大学学报.1989,10(3):247.
[12] 熊立凡,王鸿利.实验诊断学“规范检查”与循证医学[J].中国实验诊断学.2006,10(1):7-12.
[13] 赵斌华,荆永志.辅助性T细胞和抑制性T细胞对免疫反应的调控作用[J].国外医学(免疫学分册).1982,5(1):1-7.
[14] Zar ZM, Singer DR. Influx transporter variants as predictors of cancer chemotherapy-induced toxicity: systematic review and meta-analysis[J]. Pharmacogenomics. 2016, 17(10): 1189-1205.
[15] 金娟,李志鸿.西黄丸联合化疗治疗乳腺癌30例[J].中华中医药杂志.2010,25(5):715-716.
[16] 任贵兵,王磊,张府恒,等.黄连素对乳腺癌大鼠的治疗作用[J].中华实用诊断与治疗杂志,2017,31(8):747-750.